Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2023.
Related news for (VERA)
- Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
- Stocks to Watch into the Closing Bell – June 2, 2025
- Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
- Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results